Orchard secures reimbursement for gene therapy; UK fines drugmakers $47M for anticompetitive scheme
Orchard Therapeutics announced this week that the company has agreed to a reimbursement deal with England’s NHS for coverage of its gene therapy Libmeldy.
Although Orchard didn’t say how much NHS would pay for the therapy, the deal is notable because of the difficulties gene therapy developers have had coming to terms with payers, even when the therapies have been approved. In the most high-profile example, bluebird bio pulled all of its gene therapies out of Europe last year, saying countries were not offering a price commensurate with the value of its drugs for two rare blood disorders and a rare neurological condition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.